Orca is collaborating with experts at Oxford University to generate in vitro and in vivo data on Th17 biology. Collaborators include Professor Graham Ogg (psoriasis expert), Professor Paul Klenerman (Th17 cell/ILC expert), and Dr Luzheng Xue.


Under a 3 year collaboration, AstraZeneca will gain access to RORγt inhibitors developed by Orca Pharmaceuticals and will integrate these into its in-house programme. Scientists from AstraZeneca and Orca Pharmaceuticals will work together to identify lead compounds from this programme for progression and characterise the autoimmune condition to which the lead compounds are best suited. 


Brickell Biotech is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases. Under this collaboration, Brickell will continue the research and development of Orca's RORγ inhibitors, initially targeting the topical treatment of psoriasis.


Charles River Laboratories provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and leading academic institutions around the globe accelerate their research and drug development efforts. 


Orca is working with Evotec on a medicinal chemistry programme to produce orally available inhibitors of RORγt.

Become A Partner

We are open to partnering with other organization. If you or your organization is interested in partnering with Orca Pharmaceuticals, please contact us via the form below.

Name *